Gut motility and SIBO may be related, but there’s debate as to whether motility issues cause SIBO or whether SIBO causes poor motility.
Either way, prokinetics are potentially useful pharmaceutical and natural agents that can help the gut to be less sluggish and work more efficiently.
The best context for using prokinetics in SIBO is as part of an overall gut healing program that addresses underlying gut dysbiosis and inflammation (both of which can cause low motility).
By using a holistic approach, many patients will be able to address their SIBO symptoms without the use of prokinetics.
When you have SIBO, especially if it’s accompanied by a whole lot of unpleasant gut symptoms, you might feel like you’d do anything to feel better faster.
Antibiotic treatment followed by prokinetics for SIBO is one treatment combination that’s sometimes offered as the easy solution. However, as with most gut-related health issues, there’s rarely a quick fix.
In this article, we’ll look at the role of prokinetics for SIBO and what they can and can’t do for the condition and other gut issues.
What Do Prokinetics Do?
Prokinetics are medications or herbal supplements that improve the motility of the gastrointestinal system. Motility is how quickly and efficiently food is moved through the gut.
Peristalsis: the downward contractions of the GI tract that occur when it has food in it
The migrating motor complex: A wave-like motility pattern stimulated by the hormone motilin that works between meals, when the digestive tract is empty.
Prokinetic medications and natural prokinetics increase downward movement, which can help in conditions where gut motility is abnormal, such as chronic constipation, constipation dominant irritable bowel syndrome (IBS-C) and SIBO.
Prokinetics for SIBO
In SIBO, gut bacteria proliferate in the small intestine rather than the large intestine (ie, higher up the digestive tract than they should).
Many potential factors can cause or contribute to SIBO. One hypothesis is that slowed gastric emptying and reduced small intestine motility increase SIBO risk because gut contents sit around longer, allowing bad bacteria and fungi to grow [3 Trusted SourcePubMedGo to source].
It’s easy to imagine, then, how prokinetics might help in counteracting SIBO by flushing the contents of the gut downwards.
However prokinetics often aren’t always the right route for SIBO and IBS symptoms.
To begin with, while poor motility is one possible cause of SIBO, it’s likely that this problem only affects a small subset of individuals, so a treatment aimed specifically at improving motility may miss the boat for the vast majority of SIBO patients.
Even for those who do have slow motility, prokinetics might not necessarily address what’s causing that low motility: often, inflammation or gut dysbiosis.
Even where prokinetics could be helpful, a healthy diet and probiotics should be the first supports for SIBO that underpin any other treatments.
We’ll investigate a bit more where prokinetics might fit into a SIBO treatment plan later. But first, here’s a roundup of common prokinetic medications and natural prokinetics.
Stimulate peristalsis and normalise motility. *Tegaserod is older generation and has adverse effects that include cardiac arrhythmia 
A low dose stimulates the secretion of motilin hormone, which in turn activates the cyclic, recurring motility pattern (the migrating motor complex, or MMC) that occurs in the stomach and small bowel during fasting [5 Trusted SourcePubMedGo to source]
Accelerate gastric emptying in diabetic gastroparesis (incomplete stomach emptying most commonly affecting people with diabetes); acts as an antiemetic (inhibitor of vomiting) [6 Trusted SourcePubMedGo to source] *Domperidone is no longer routinely available in the USA
Improved the frequency and consistency of bowel movements in one clinical trial 
Standardized combination of artichoke and ginger extracts
Found to be 24% better than placebo at improving motility after a meal, suggesting efficacy as a prokinetic agent [21 Trusted SourcePubMedGo to source]
SIBO, Motility, and Autoimmunity
Gut motility issues, including faster or slower transit times, can result from an autoimmune problem occurring in the aftermath of an infection such as food poisoning, a stomach virus, or traveler’s diarrhea.
In this case, the immune system system can damage cells called interstitial cells of Cajal, which play an important role in regulating motility [22 Trusted SourcePubMedGo to source].
Testing for antibodies known as anti-CdtB antibodies and anti-vinculin antibodies can assess if this sort of immune damage has occurred. However, it is not something I tend to do routinely with my SIBO/IBS patients, as it isn’t always that informative.
For example, a 2017 observation study found that the presence of both these antibodies tended to predict IBS-D (diarrhea predominant IBS) reasonably well. However, 26.7% of people with IBS-C (constipation dominant IBS) still had the antibodies, as did 16.3% of people with no symptoms at all [23 Trusted SourcePubMedGo to source].
Similarly, a 2021 study found no statistical difference between the levels of anti-CdtB antibodies among those with functional GI disorders (including IBS) and healthy individuals [24 Trusted SourcePubMedGo to source].
Overall, it’s likely that the autoimmunity-driven dysmotility theory behind IBS and SIBO has been overstated.
The Role of Inflammation and Dysbiosis
While the autoimmunity hypothesis above suggests that dysmotility problems in the gut cause SIBO, there’s also some evidence that the other way round is true — ie, the gut bacteria imbalances and inflammation that come with SIBO cause gut dysmotility issues [25 Trusted SourcePubMedGo to source].
This is another reason why tackling inflammation and dysbiosis is so important for those with SIBO and IBS. For example:
An observational study found inflammation to be a major driver of motility problems in inflammatory bowel disease (Crohn’s disease patients) [26 Trusted SourcePubMedGo to source].
Studies in which gut biopsies are tested in the lab show that inflammation interferes with the ability of the human small intestine to contract properly [27 Trusted SourcePubMedGo to source].
In patients with type 2 diabetes, the presence of SIBO has been associated with delayed gut transit, pointing to an association between gut microbial dysbiosis, GI dysmotility, and metabolic disorder [28 Trusted SourcePubMedGo to source].
Rather than hopping straight to prokinetics for SIBO or IBS, it’s therefore a good idea to deal with inflammation and gut bacteria imbalances and allow your gut motility apparatus (and your overall gut health) to repair naturally. This approach has worked best for most of my patients and fits with research that shows the interstitial cells of Cajal (ICC) —intestinal cells involved in healthy gut motility — can repair themselves in about 6 months even after significant autoimmune damage [29 Trusted SourcePubMedGo to source, 30 Trusted SourcePubMedGo to source, 31 Trusted SourcePubMedGo to source].
Diet and Lifestyle Alternatives to Prokinetics
The most effective approach to dealing with SIBO and IBS symptoms is a comprehensive gut healing program. Remember, prokinetics are not for everyone, and they cannot replace good nutrition and lifestyle habits.
The most important part, and the first place to start, is your diet. Giving extra support to your gut microbiome with the right probiotics will also help, as of course will a healthy, physically active lifestyle.
Let’s have a look at these one by one:
Healthy Eating (the Low FODMAP Diet)
Cutting down on inflammatory processed foods and sugar will help with gut symptoms almost straight away. Healthy whole foods such as vegetables, whole grains, and lean proteins are the basis of most healthy eating regimens that reduce inflammation and control blood sugar. But for SIBO and IBS in particular, the low-FODMAP diet may be most pertinent.
One review of 10 clinical trials found that the low-FODMAP diet resulted in several positive changes in the microbiome, and in overall gut health, including [32 Trusted SourcePubMedGo to source]:
A less leaky gut
Reduced histamine (a marker of an overzealous immune system)
An advantage of the low-FODMAP diet is that though it may be somewhat restrictive at first, as your SIBO improves, you should gradually be able to reintroduce and tolerate foods that were previously problematic.
To complement positive diet changes, adding a daily probiotic supplement is the next really useful step. Despite some reports to the contrary, probiotics are a safe, excellent and well evaluated treatment for SIBO [36 Trusted SourcePubMedGo to source].
A meta-analysis summarizing 18 clinical trials concluded that probiotics are an effective treatment for SIBO. Specifically, probiotics reduced bacterial overgrowth and hydrogen concentrations and improved symptoms including abdominal pain [36 Trusted SourcePubMedGo to source].
Another study found that probiotics work better in patients with both IBS and SIBO as compared to those who have IBS without SIBO [38 Trusted SourcePubMedGo to source].
A Three-Prong Approach
Research has observed that multi species probiotics work best, for example for alleviating IBS symptoms [39 Trusted SourcePubMedGo to source, 40 Trusted SourcePubMedGo to source]. Some of the best success we’ve seen in the clinic with SIBO patients has been when these three types of probiotics were administered at the same time:
These three types of probiotics work together like the legs of a three-legged stool. If the stool only has one or two legs, it’s likely to be unstable. With three legs, the stool is able to stay upright.
If some of your symptoms still remain after you’ve made diet and lifestyle changes and been taking probiotics for a month or so, it’s time to consider other ways to support your gut.
In the phased protocol described in Healthy Gut, Healthy You, antimicrobials are the next logical step, with prokinetics something to consider after that.
Given the ability of antibiotics and antimicrobials (even natural versions) to blast bad bugs [45, 46 Trusted SourcePubMedGo to source], it might be tempting to opt for microbials earlier on in your gut treatment pathway. However, lots of clinical experience and good practice guidelines from around the world suggest otherwise.
For example, the 2021 IBS treatment guidelines from the British Society of Gastroenterology and Romanian Society of Neurogastroenterology reflect that the treatment order should be diet. probiotics and then antimicrobials [47 Trusted SourcePubMedGo to source, 48 Trusted SourcePubMedGo to source].
Antimicrobials that can help SIBO patients include the following:
You can work with a practitioner to find out which antimicrobial works best for you. If you decide this is Rifaximin, you’ll need a doctor’s prescription for this pharmaceutical antibiotic. However many patients prefer to work with natural antimicrobials, such as ginger, peppermint oil and other herbals, that can still have potent effects [46 Trusted SourcePubMedGo to source] but may be less likely to contribute to antibiotic resistance [49 Trusted SourcePubMedGo to source].
The theory behind using prokinetics after antibiotics is that they help to maintain good motility and prevent bad bacteria from building up again. If you have SIBO-associated IBS-C (which tends to correlate with a positive methane breath test) you are likely a good candidate for prokinetics.
Evidence that supports the use of prokinetics for SIBO and other motility problems includes:
A review of randomized controlled trials (RCTs) that found several different prokinetics accelerated gastric emptying and reduced upper gastrointestinal symptoms [6 Trusted SourcePubMedGo to source].
Research showing long-term users of PPI (proton pump inhibitor) medications had a faster gut motility and a lower risk of SIBO (associated with long-term PPI use) when they add prokinetics to their regimen [51 Trusted SourcePubMedGo to source].
Six RCTs found that patients receiving prucalopridewere more likely to experience an increase in complete spontaneous bowel movements (to at least three per week) than those who received a placebo .
However not all the research is clear-cut, nor are prokinetics a silver bullet. For example:
A 2011 systematic review of eight RCTs (424 patients with constipation or IBS-C) found that the prokinetic cisapride demonstrated no clear benefit over placebo [53 Trusted SourcePubMedGo to source].
In an observational study, patients with various gut symptoms were prescribed the prokinetic low-dose naltrexone. The study found that of the 85 patients with IBS and SIBO [7 Trusted SourcePubMedGo to source]:
15 (17.6%) got much better
32 (37.6%) got moderately worse
1 (1.2%) became much worse
Treatment of SIBO with prokinetics (following antibiotics) extended the period before bacterial regrowth, but relapse still occurred within 5–7 months (versus two months later if no prokinetic was used [54 Trusted SourcePubMedGo to source].
Which prokinetic to choose for SIBO, and when, is something you can work out with a practitioner or by following the great-in-8 protocol. If you are going it alone, remember that you won’t get the stronger acting pharmaceutical prokinetics without a prescription. Many people find they prefer to start with gentle natural prokinetic agents such as ginger, anyway.
The Bottom Line
Prokinetics help improve gut motility and can be of help in SIBO, but a good effect isn’t guaranteed, nor should prokinetics be the first or only treatment. Diet changes, probiotics and antimicrobials should come first. SIBO relapses can happen even if you do use prokinetics and reducing these relapses and eventually reaching a point where your gut is completely well again takes a multi-pronged approach. For expert help tailoring prokinetics and SIBO treatment to your needs, consider a consultation at my functional medicine center.
Al-Shboul OA. The importance of interstitial cells of cajal in the gastrointestinal tract. Saudi J Gastroenterol. 2013 Feb;19(1):3–15. DOI: 10.4103/1319-3767.105909. PMID: 23319032. PMCID: PMC3603487. Trusted SourcePubMedGo to source
Quigley EMM. Prokinetics in the management of functional gastrointestinal disorders. J Neurogastroenterol Motil. 2015 Jul 30;21(3):330–6. DOI: 10.5056/jnm15094. PMID: 26130629. PMCID: PMC4496896. Trusted SourcePubMedGo to source
Vijayvargiya P, Camilleri M, Chedid V, Mandawat A, Erwin PJ, Murad MH. Effects of Promotility Agents on Gastric Emptying and Symptoms: A Systematic Review and Meta-analysis. Gastroenterology. 2019 May;156(6):1650–60. DOI: 10.1053/j.gastro.2019.01.249. PMID: 30711628. Trusted SourcePubMedGo to source
Patten DK, Schultz BG, Berlau DJ. The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn’s Disease, and Other Chronic Pain Disorders. Pharmacotherapy. 2018 Mar;38(3):382–9. DOI: 10.1002/phar.2086. PMID: 29377216. Trusted SourcePubMedGo to source
Madisch A, Vinson BR, Abdel-Aziz H, Kelber O, Nieber K, Kraft K, et al. Modulation of gastrointestinal motility beyond metoclopramide and domperidone : Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders. Wien Med Wochenschr. 2017 May;167(7–8):160–8. DOI: 10.1007/s10354-017-0557-3. PMID: 28424994. PMCID: PMC5409921. Trusted SourcePubMedGo to source
Gundermann KJ, Godehardt E, Ulbrich M. [The efficacy of a combination herbal medicine in the treatment of functional dyspepsia. Meta-analysis of randomized double-blind studies on the basis of a valid gastrointestinal symptom profile]. MMW Fortschr Med. 2004 Aug 5;146 Suppl 2:71–6. PMID: 16739362. Trusted SourcePubMedGo to source
Gundermann K-J, Godehardt E, Ulbrich M. Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials. Adv Ther. 2003 Feb;20(1):43–9. DOI: 10.1007/BF02850118. PMID: 12772817. Trusted SourcePubMedGo to source
Lete I, Allué J. The Effectiveness of Ginger in the Prevention of Nausea and Vomiting during Pregnancy and Chemotherapy. Integr Med Insights. 2016 Mar 31;11:11–7. DOI: 10.4137/IMI.S36273. PMID: 27053918. PMCID: PMC4818021. Trusted SourcePubMedGo to source
Wu K-L, Rayner CK, Chuah S-K, Changchien C-S, Lu S-N, Chiu Y-C, et al. Effects of ginger on gastric emptying and motility in healthy humans. Eur J Gastroenterol Hepatol. 2008 May;20(5):436–40. DOI: 10.1097/MEG.0b013e3282f4b224. PMID: 18403946. Trusted SourcePubMedGo to source
Phillips S, Hutchinson S, Ruggier R. Zingiber officinale does not affect gastric emptying rate. A randomised, placebo-controlled, crossover trial. Anaesthesia. 1993 May;48(5):393–5. DOI: 10.1111/j.1365-2044.1993.tb07011.x. PMID: 8317647. Trusted SourcePubMedGo to source
Hawrelak JA, Wohlmuth H, Pattinson M, Myers SP, Goldenberg JZ, Harnett J, et al. Western herbal medicines in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Complement Ther Med. 2020 Jan;48:102233. DOI: 10.1016/j.ctim.2019.102233. PMID: 31987249. Trusted SourcePubMedGo to source
Tan N, Gwee KA, Tack J, Zhang M, Li Y, Chen M, et al. Herbal medicine in the treatment of functional gastrointestinal disorders: A systematic review with meta-analysis. J Gastroenterol Hepatol. 2020 Apr;35(4):544–56. DOI: 10.1111/jgh.14905. PMID: 31674057. Trusted SourcePubMedGo to source
Black CJ, Yuan Y, Selinger CP, Camilleri M, Quigley EMM, Moayyedi P, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(2):117–31. DOI: 10.1016/S2468-1253(19)30324-3. PMID: 31859183. Trusted SourcePubMedGo to source
Mosaffa-Jahromi M, Lankarani KB, Pasalar M, Afsharypuor S, Tamaddon A-M. Efficacy and safety of enteric coated capsules of anise oil to treat irritable bowel syndrome. J Ethnopharmacol. 2016 Dec 24;194:937–46. DOI: 10.1016/j.jep.2016.10.083. PMID: 27815079. Trusted SourcePubMedGo to source
Mukherjee P, Rai S, Bhattacharyya S, Debnath P, Biswas T, Jana U, et al. Clinical Study of “Triphala” – A Well Known Phytomedicine from India. Iranian Journal of Pharmacology and Therapeutics. 2006;
Lazzini S, Polinelli W, Riva A, Morazzoni P, Bombardelli E. The effect of ginger (Zingiber officinalis) and artichoke (Cynara cardunculus) extract supplementation on gastric motility: a pilot randomized study in healthy volunteers. Eur Rev Med Pharmacol Sci. 2016;20(1):146–9. PMID: 26813467. Trusted SourcePubMedGo to source
Pimentel M, Morales W, Rezaie A, Marsh E, Lembo A, Mirocha J, et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS ONE. 2015 May 13;10(5):e0126438. DOI: 10.1371/journal.pone.0126438. PMID: 25970536. PMCID: PMC4430499. Trusted SourcePubMedGo to source
Rezaie A, Park SC, Morales W, Marsh E, Lembo A, Kim JH, et al. Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome. Dig Dis Sci. 2017 Jun;62(6):1480–5. DOI: 10.1007/s10620-017-4585-z. PMID: 28451914. Trusted SourcePubMedGo to source
Vasapolli R, Schulz C, Schweden M, Casèn C, Kirubakaran GT, Kirste KH, Macke L, Link A, Schütte K, Malfertheiner P. Gut microbiota profiles and the role of anti-CdtB and anti-vinculin antibodies in patients with functional gastrointestinal disorders (FGID). Eur J Clin Invest. 2021 Aug 14:e13666. doi: 10.1111/eci.13666. Epub ahead of print. PMID: 34390492. Trusted SourcePubMedGo to source
Singh R, Zogg H, Wei L, Bartlett A, Ghoshal UC, Rajender S, et al. Gut microbial dysbiosis in the pathogenesis of gastrointestinal dysmotility and metabolic disorders. J Neurogastroenterol Motil. 2021 Jan 30;27(1):19–34. DOI: 10.5056/jnm20149. PMID: 33166939. PMCID: PMC7786094. Trusted SourcePubMedGo to source
Menys A, Makanyanga J, Plumb A, Bhatnagar G, Atkinson D, Emmanuel A, et al. Aberrant motility in unaffected small bowel is linked to inflammatory burden and patient symptoms in crohn’s disease. Inflamm Bowel Dis. 2016 Feb;22(2):424–32. DOI: 10.1097/MIB.0000000000000601. PMID: 26509756. Trusted SourcePubMedGo to source
Al-Saffar A, Hellström PM. Contractile responses to natural tachykinins and selective tachykinin analogs in normal and inflamed ileal and colonic muscle. Scand J Gastroenterol. 2001 May;36(5):485–93. PMID: 11346201. Trusted SourcePubMedGo to source
Rana SV, Malik A, Bhadada SK, Sachdeva N, Morya RK, Sharma G. Malabsorption, orocecal transit time and small intestinal bacterial overgrowth in type 2 diabetic patients: A connection. Indian J Clin Biochem. 2017 Mar;32(1):84–9. DOI: 10.1007/s12291-016-0569-6. PMID: 28149017. PMCID: PMC5247367. Trusted SourcePubMedGo to source
Mei F, Yu B, Ma H, Zhang HJ, Zhou DS. Interstitial cells of Cajal could regenerate and restore their normal distribution after disrupted by intestinal transection and anastomosis in the adult guinea pigs. Virchows Arch. 2006 Sep;449(3):348-57. doi: 10.1007/s00428-006-0258-6. Epub 2006 Aug 16. PMID: 16912883. Trusted SourcePubMedGo to source
Mei F, Han J, Huang Y, Jiang ZY, Xiong CJ, Zhou DS. Plasticity of interstitial cells of cajal: a study in the small intestine of adult Guinea pigs. Anat Rec (Hoboken). 2009 Jul;292(7):985-93. doi: 10.1002/ar.20928. PMID: 19548308. Trusted SourcePubMedGo to source
Sigurdsson L, Flores A, Putnam PE, Hyman PE, Di Lorenzo C. Postviral gastroparesis: presentation, treatment, and outcome. J Pediatr. 1997 Nov;131(5):751-4. doi: 10.1016/s0022-3476(97)70106-9. PMID: 9403659. Trusted SourcePubMedGo to source
Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut. 2017 Aug;66(8):1517–27. DOI: 10.1136/gutjnl-2017-313750. PMID: 28592442. Trusted SourcePubMedGo to source
Marsh A, Eslick EM, Eslick GD. Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis. Eur J Nutr. 2016 Apr;55(3):897–906. DOI: 10.1007/s00394-015-0922-1. PMID: 25982757. Trusted SourcePubMedGo to source
Schumann D, Klose P, Lauche R, Dobos G, Langhorst J, Cramer H. Low fermentable, oligo-, di-, mono-saccharides and polyol diet in the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Nutrition. 2018 Jan;45:24–31. DOI: 10.1016/j.nut.2017.07.004. PMID: 29129233. Trusted SourcePubMedGo to source
Altobelli E, Del Negro V, Angeletti PM, Latella G. Low-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis. Nutrients. 2017 Aug 26;9(9). DOI: 10.3390/nu9090940. PMID: 28846594. PMCID: PMC5622700. Trusted SourcePubMedGo to source
Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence. J Clin Gastroenterol. 2017 Apr;51(4):300–11. DOI: 10.1097/MCG.0000000000000814. PMID: 28267052. Trusted SourcePubMedGo to source
Soifer LO, Peralta D, Dima G, Besasso H. [Comparative clinical efficacy of a probiotic vs. an antibiotic in the treatment of patients with intestinal bacterial overgrowth and chronic abdominal functional distension: a pilot study]. Acta Gastroenterol Latinoam. 2010 Dec;40(4):323–7. PMID: 21381407. Trusted SourcePubMedGo to source
Leventogiannis K, Gkolfakis P, Spithakis G, Tsatali A, Pistiki A, Sioulas A, et al. Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth. Probiotics Antimicrob Proteins. 2019 Jun;11(2):627–34. DOI: 10.1007/s12602-018-9401-3. PMID: 29508268. PMCID: PMC6541575. Trusted SourcePubMedGo to source
American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009 Jan;104 Suppl 1:S1-35. DOI: 10.1038/ajg.2008.122. PMID: 19521341. Trusted SourcePubMedGo to source
Ford AC, Quigley EMM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014 Oct;109(10):1547–61; quiz 1546, 1562. DOI: 10.1038/ajg.2014.202. PMID: 25070051. Trusted SourcePubMedGo to source
Kim YS, Song BK, Oh JS, Woo SS. Aerobic exercise improves gastrointestinal motility in psychiatric inpatients. World J Gastroenterol. 2014 Aug 14;20(30):10577–84. DOI: 10.3748/wjg.v20.i30.10577. PMID: 25132778. PMCID: PMC4130869. Trusted SourcePubMedGo to source
Meshkinpour H, Selod S, Movahedi H, Nami N, James N, Wilson A. Effects of regular exercise in management of chronic idiopathic constipation. Dig Dis Sci. 1998 Nov;43(11):2379–83. DOI: 10.1023/a:1026609610466. PMID: 9824122. Trusted SourcePubMedGo to source
Everhart JE, Go VL, Johannes RS, Fitzsimmons SC, Roth HP, White LR. A longitudinal survey of self-reported bowel habits in the United States. Dig Dis Sci. 1989 Aug;34(8):1153–62. DOI: 10.1007/BF01537261. PMID: 2787735. Trusted SourcePubMedGo to source
Mailing LJ, Allen JM, Buford TW, Fields CJ, Woods JA. Exercise and the gut microbiome: A review of the evidence, potential mechanisms, and implications for human health. Exerc Sport Sci Rev. 2019 Apr;47(2):75–85. DOI: 10.1249/JES.0000000000000183. PMID: 30883471. Trusted SourcePubMedGo to source
Ionescu MI. Are herbal products an alternative to antibiotics? In: Kırmusaoğlu S, editor. Bacterial pathogenesis and antibacterial control. InTech; 2018. DOI: 10.5772/intechopen.72110.
Chedid V, Dhalla S, Clarke JO, Roland BC, Dunbar KB, Koh J, et al. Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 2014 May;3(3):16–24. DOI: 10.7453/gahmj.2014.019. PMID: 24891990. PMCID: PMC4030608. Trusted SourcePubMedGo to source
Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021 Jul;70(7):1214–40. DOI: 10.1136/gutjnl-2021-324598. PMID: 33903147. Trusted SourcePubMedGo to source
Dumitrascu DL, Baban A, Bancila I, Barboi O, Bataga S, Chira A, et al. Romanian guidelines for nonpharmacological therapy of IBS. J Gastrointestin Liver Dis. 2021 Jun 18;30(2):291–306. DOI: 10.15403/jgld-3581. PMID: 33951120. Trusted SourcePubMedGo to source
Anand U, Jacobo-Herrera N, Altemimi A, Lakhssassi N. A comprehensive review on medicinal plants as antimicrobial therapeutics: potential avenues of biocompatible drug discovery. Metabolites. 2019 Nov 1;9(11). DOI: 10.3390/metabo9110258. PMID: 31683833. PMCID: PMC6918160. Trusted SourcePubMedGo to source
Mozaffari S, Nikfar S, Abdollahi M. Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome. Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):403–21. DOI: 10.1517/17425255.2013.759558. PMID: 23330973. Trusted SourcePubMedGo to source
Revaiah PC, Kochhar R, Rana SV, Berry N, Ashat M, Dhaka N, et al. Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics. JGH Open. 2018 Apr 2;2(2):47–53. DOI: 10.1002/jgh3.12045. PMID: 30483563. PMCID: PMC6206996. Trusted SourcePubMedGo to source
Aboumarzouk OM, Agarwal T, Antakia R, Shariff U, Nelson RL. Cisapride for intestinal constipation. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD007780. DOI: 10.1002/14651858.CD007780.pub2. PMID: 21249695. Trusted SourcePubMedGo to source
Pimentel M, Morales W, Lezcano S, Sun-Chuan D, Low K, Yang J. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y). 2009 Jun;5(6):435–42. PMID: 20574504. PMCID: PMC2886395. Trusted SourcePubMedGo to source
I care about answering your questions and sharing my knowledge with you. Leave a comment or connect with me on social media asking any health question you may have and I just might incorporate it into our next listener questions podcast episode just for you!
Transform your health
Every product is science-based, validated by real-world use, and personally vetted by Dr. Ruscio, DNM, DC.